secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENvue Medical, Inc. (FEED)
CIK:        0001326706
Form:       8-K
Filed at:   2023-09-27T23:59:59+00:00
Accession:  0001493152-23-033834
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NanoVibronix receives NHS Drug Tariff approval for UroShield actuators; contract extended to 4 years
--------------------------------------------------------------------------------

- NHS Drug Tariff approval enables full reimbursement of UroShield actuators starting November 1, 2023 for clinicians to prescribe.
- NHS Supply Chain contract extended up to four years via UK distribution partner Peak Medical Limited.
- CEO Brian Murphy: reimbursement removes critical barrier; expects increased unit sales and production to meet demand.
- UroShield is used for preventing Catheter-Associated Urinary Tract Infections (CAUTIs) in patients with indwelling catheters.
- Patients can now receive full UroShield system with NHS covering cost, not patient.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326706/000149315223033834/0001493152-23-033834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326706/000149315223033834/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-033834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer